Monoclonal Anti- Cancerous inhibitor of protein phosphatase 2A, Protein CIP2A Antibody

Catalog# BMA1008

Lot # Check on the product label

Size 100μg

Isotype IgM

Clone # S17-6

Host Mouse

Reactivity Human, mouse

Product Form Liquid

Purification Protein A or Protein G purified

Immunogen 

Recombinant CIP2A protein.

Recommend Application

Western blot, WB (1:1000-10000)

Immunocytochemistry, ICC (1:100-200)

Immunohistochemistry, IHC-P (1:50)

Other applications have not been tested.

The optimal dilutions should be determined by end user.

Storage Buffer

In TBS (pH7.4), 0.5% BSA, 40% Glycerol and 0.05% Sodium Azide.

Storage Instruction 

Store at 4°C after thawing (1 week). Aliquot and store at -20°C for long term (at least one year).

Avoid repeated freeze and thaw cycles.

Background

Cancerous inhibitor of protein phosphatase 2A (CIP2A), also known as p90 autoantigen or KIAA1524, is a cellular tumor suppressor which inhibits cell proliferation and transformation of normal cells to malignant cancer cells. It has a calculated molecular mass of 102.2 kD and has a 255-amino acid coiled-coil region at its C terminus. RT-PCR ELISA detected moderate expression in fetal liver and low expression in adult liver, spleen, ovary, and whole brain, as well as in all specific brain regions examined. CIP2A is also over expressed in prostate cancer, lung cancer, oral squamous cell carcinoma, and gastric cancer. Furthermore, the expression of CIP2A correlates with breast cancer aggressivity.

Reference

1. Nagase, T., Kikuno, R., Ishikawa, K., Hirosawa, M., Ohara, O. Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 7: 143-150, 2000.

2. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH (September 2010). "CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis". Ann Surg Oncol 18 (3): 857–865.

3. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A (June 2009). "MYC-dependent regulation and prognostic role of CIP2A in gastric cancer". J. Natl. Cancer Inst. 101 (11): 793–805.

4. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J (August 2009). "CIP2A is associated with human breast cancer aggressivity".